Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J van Rossum

Showing results (131-140 of 147) with videos related to

Pageof 15
Sort By:
Journal of Clinical Medicine|October 13, 2021
Reliability of the Preliminary OMERACT Juvenile Idiopathic Arthritis MRI Score (OMERACT JAMRIS-SIJ)Tarimobo M Otobo, Nele Herregods, Jacob L Jaremko, et al.
Annals of the Rheumatic Diseases|December 19, 2013
Genetic variation in VTCN1 (B7-H4) is associated with course of disease in juvenile idiopathic arthritisH M Albers, T H C M Reinards, D M C Brinkman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2026
PI3K inhibition in combination with tamoxifen in patients with metastatic HR+/HER2- breast cancer: clinical and circulating tumor DNA resultsRosie A B Voorthuis, Mafalda Oliveira, Annelot G J van Rossum, et al.
Annals of the Rheumatic Diseases|June 26, 2012
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterMarieke H Otten, Femke H M Prince, Janneke Anink, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children RegisterMarieke H Otten, Janneke Anink, Femke H M Prince, et al.
Annals of the Rheumatic Diseases|July 25, 2014
CD226 (DNAM-1) is associated with susceptibility to juvenile idiopathic arthritisT H C M Reinards, H M Albers, D M C Brinkman, et al.
Clinical and Experimental Rheumatology|May 30, 2012
Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitidesErkan Demirkaya, Seza Ozen, Angela Pistorio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB TrialSonja B Vliek, Iris Noordhoek, Elma Meershoek-Klein Kranenbarg, et al.
Rheumatology (Oxford, England)|June 7, 2013
Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?Janneke Anink, Marieke H Otten, Simone L Gorter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer PatientsRichard D Baird, Annelot G J van Rossum, Mafalda Oliveira, et al.
Pageof 15

Showing results (131-140 of 147) with videos related to

Sort By:
Pageof 15
Journal of Clinical Medicine|October 13, 2021
Reliability of the Preliminary OMERACT Juvenile Idiopathic Arthritis MRI Score (OMERACT JAMRIS-SIJ)Tarimobo M Otobo, Nele Herregods, Jacob L Jaremko, et al.
Annals of the Rheumatic Diseases|December 19, 2013
Genetic variation in VTCN1 (B7-H4) is associated with course of disease in juvenile idiopathic arthritisH M Albers, T H C M Reinards, D M C Brinkman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2026
PI3K inhibition in combination with tamoxifen in patients with metastatic HR+/HER2- breast cancer: clinical and circulating tumor DNA resultsRosie A B Voorthuis, Mafalda Oliveira, Annelot G J van Rossum, et al.
Annals of the Rheumatic Diseases|June 26, 2012
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterMarieke H Otten, Femke H M Prince, Janneke Anink, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children RegisterMarieke H Otten, Janneke Anink, Femke H M Prince, et al.
Annals of the Rheumatic Diseases|July 25, 2014
CD226 (DNAM-1) is associated with susceptibility to juvenile idiopathic arthritisT H C M Reinards, H M Albers, D M C Brinkman, et al.
Clinical and Experimental Rheumatology|May 30, 2012
Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitidesErkan Demirkaya, Seza Ozen, Angela Pistorio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB TrialSonja B Vliek, Iris Noordhoek, Elma Meershoek-Klein Kranenbarg, et al.
Rheumatology (Oxford, England)|June 7, 2013
Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?Janneke Anink, Marieke H Otten, Simone L Gorter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer PatientsRichard D Baird, Annelot G J van Rossum, Mafalda Oliveira, et al.
Pageof 15